This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Why Amgen (AMGN) Outpaced the Stock Market Today
by Zacks Equity Research
In the most recent trading session, Amgen (AMGN) closed at $271.48, indicating a +0.95% shift from the previous trading day.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
by Zacks Equity Research
Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.
Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Amgen (AMGN) concluded the recent trading session at $264.07, signifying a -0.59% move from its prior day's close.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Amgen (AMGN) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the most recent trading session, Amgen (AMGN) closed at $270, indicating a +1.33% shift from the previous trading day.
Biophytis (BPTS) to Begin Phase II Obesity Study, Stock Up
by Zacks Equity Research
Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.
3 Top Dividend Stocks to Maximize Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Amgen (AMGN) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
Amgen (AMGN) concluded the recent trading session at $269.95, signifying a +0.69% move from its prior day's close.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate
by Zacks Equity Research
Merck's (MRK) phase III study will evaluate KRAS G12C inhibitor candidate MK-1084 for first-line treatment of certain patients with metastatic NSCLC.
Here's Why Amgen (AMGN) Stock is Outperforming the Industry
by Zacks Equity Research
Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to make up for lower revenues from oncology biosimilars and Enbrel
Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $283.04, moving -0.45% from the previous trading session.
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -211.67% and 75.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Awaits Consumer Confidence Data
by Zacks Equity Research
Wall Street Awaits Consumer Confidence Data
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
Wall Street Set to Post Fifth Winning Month Amid Volatility
by Zacks Equity Research
Wall Street is likely to record the fifth consecutive winning month despite volatility.
Amgen (AMGN) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the most recent trading session, Amgen (AMGN) closed at $280.82, indicating a +1.68% shift from the previous trading day.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?